# Ozempic, Wegovy, Mounjaro or Zepbound not working?

Source: https://pepvault.app/guides/glp-1-not-working

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials

Reviewed November 2026 13 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

GLP-1 not working? The four labels side by side: how many lost under 5% in the trials, why diabetes slows loss, slow starters, and what a higher dose did.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 13
- **Questions:** 7
- **Compounds:** 2

## The short answer

Often it is too early. Every label starts on a dose meant only to begin: Wegovy reaches 2.4 mg in week 17, Zepbound 15 mg in week 21 at the earliest. On the top doses, 84 to 91% of trial participants without diabetes lost at least 5%, fewer with diabetes, and most tirzepatide users below 5% at week 12 had passed it by week 72.

Every number checked at its primary source · Nov 20, 2026 · [13 sources](https://pepvault.app/guides/glp-1-not-working#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** FDA labels for all four drugs and randomised phase 3 trials in people, with responder shares from the labels; slow-responder data from a Lilly-run post-hoc analysis of SURMOUNT-1; NICE guidance for the 6-month test.

## Is my GLP-1 not working, or is it too early?

Most early stalls happen on doses never meant to do the work. Wegovy starts at 0.25 mg and reaches its 2.4 mg maintenance dose only in week 17[1](https://pepvault.app/guides/glp-1-not-working#source-1). Zepbound's label says its 2.5 mg starting dose 'is for treatment initiation and is not approved as a maintenance dosage', and each step after it lasts at least four weeks, so 15 mg arrives in week 21 at the earliest[2](https://pepvault.app/guides/glp-1-not-working#source-2).

<!--promo-->

PepVault's dose log keeps every shot with its date and amount, so you can see which step you are on and how many weeks you have been on it. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1-not-working-inline&mt=8)

<!--/promo-->

| Label (as of November 20, 2026) | Approved for | How the dose climbs | Highest dose | Earliest week on it |
| --- | --- | --- | --- | --- |
| Ozempic[3](https://pepvault.app/guides/glp-1-not-working#source-3) | Type 2 diabetes, with heart and kidney risk | 0.25 mg for 4 weeks, then 0.5 mg; 1 mg and 2 mg 'if additional glycemic control is needed', each after 4+ weeks | 2 mg | 13 |
| Wegovy[1](https://pepvault.app/guides/glp-1-not-working#source-1) | Weight, heart risk, MASH liver disease | 0.25, 0.5, 1 and 1.7 mg, four weeks each; 7.2 mg only after 4+ weeks on 2.4 mg | 2.4 mg (7.2 mg) | 17 (for 2.4 mg) |
| Mounjaro[4](https://pepvault.app/guides/glp-1-not-working#source-4) | Type 2 diabetes, with heart risk | 2.5 mg, then 2.5 mg more after 4+ weeks 'if additional glycemic control is needed' | 15 mg | 21 |
| Zepbound[2](https://pepvault.app/guides/glp-1-not-working#source-2) | Weight, sleep apnea | 2.5 mg for 4 weeks, then 2.5 mg more after 4+ weeks | 15 mg | 21 |

On Ozempic and Mounjaro, the labels raise the dose for blood sugar, not weight, so someone whose sugar is under control can stay on a lower dose than the obesity trials used[3](https://pepvault.app/guides/glp-1-not-working#source-3) [4](https://pepvault.app/guides/glp-1-not-working#source-4). And a new step keeps building for weeks. Semaglutide's half-life, the time the body takes to clear half a dose, is about a week; tirzepatide's is five to six days[1](https://pepvault.app/guides/glp-1-not-working#source-1) [2](https://pepvault.app/guides/glp-1-not-working#source-2). A weekly drug settles at its steady state (pepvault.app/glossary/steady-state) after about four to five half-lives, roughly a month, and semaglutide's steady-state level rose in proportion to the dose all the way to 7.2 mg[1](https://pepvault.app/guides/glp-1-not-working#source-1).

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Semaglutide in the library](https://pepvault.app/peptides/semaglutide)

Missed doses reset the clock too. After two or more missed Wegovy doses in a row, the label restarts the climb at a lower dose[1](https://pepvault.app/guides/glp-1-not-working#source-1).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's dose log keeps every shot with its date and amount, so you can see which step you are on and how many weeks you have been on it.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How many people lost less than 5% in the trials?

Fewer than one in six on the top doses, counting everyone who was randomised, including people who stopped the drug. The Wegovy and Zepbound labels give the share of each group that reached three marks[1](https://pepvault.app/guides/glp-1-not-working#source-1) [2](https://pepvault.app/guides/glp-1-not-working#source-2). A 5% loss is 5 kg, or 11 lb, from a start of 100 kg (220 lb).

| Trial in the label, no diabetes | Group | Lost 5% or more | Lost 10% or more | Lost 15% or more |
| --- | --- | --- | --- | --- |
| Wegovy Study 2 (STEP 1), 68 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | Placebo | 31.1% | 12% | 4.8% |
| Wegovy Study 2 (STEP 1), 68 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | 2.4 mg | 83.5% | 66.1% | 47.9% |
| Wegovy Study 8 (STEP UP), 72 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | Placebo | 38.3% | 20.3% | 7.5% |
| Wegovy Study 8 (STEP UP), 72 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | 2.4 mg | 86.6% | 72% | 52.3% |
| Wegovy Study 8 (STEP UP), 72 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | 7.2 mg | 88.7% | 79.8% | 63.8% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | Placebo | 34.5% | 18.8% | 8.8% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | 5 mg | 85.1% | 68.5% | 48.0% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | 10 mg | 88.9% | 78.1% | 66.6% |
| Zepbound Study 1 (SURMOUNT-1), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | 15 mg | 90.9% | 83.5% | 70.6% |

A loss under 5% happened to about 16.5% of people on Wegovy 2.4 mg in STEP 1 and 9.1% on Zepbound 15 mg, and each higher dose moved more people past every mark, most of all at 15%. Counting only what people weighed, without filling in the missing weights, STEP 1's paper puts the 5% share on semaglutide at 86.4%[5](https://pepvault.app/guides/glp-1-not-working#source-5). A 2026 review of response to these drugs puts non-response, a loss under 5%, at about 10% of people without diabetes in controlled trials, and higher in everyday practice[10](https://pepvault.app/guides/glp-1-not-working#source-10).

The label shares come from statistical models that fill in missing weights, and every group also had diet and activity counselling. About a third of the placebo groups reached 5% without the drug.

## Does type 2 diabetes slow weight loss on a GLP-1?

Yes, in every pair of label trials run at the same dose. With type 2 diabetes, a third of people on Wegovy 2.4 mg stayed under 5% in STEP 2, against about one in six without diabetes in STEP 1[1](https://pepvault.app/guides/glp-1-not-working#source-1).

| Trial in the label, type 2 diabetes | Group | Lost 5% or more | Lost 10% or more | Lost 15% or more |
| --- | --- | --- | --- | --- |
| Wegovy Study 3 (STEP 2), 68 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | Placebo | 30.2% | 10.2% | 4.3% |
| Wegovy Study 3 (STEP 2), 68 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | 2.4 mg | 67.4% | 44.5% | 25.1% |
| Wegovy Study 9 (STEP UP T2D), 72 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | Placebo | 34% | 11.2% | 6.9% |
| Wegovy Study 9 (STEP UP T2D), 72 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | 2.4 mg | 74% | 49.5% | 27% |
| Wegovy Study 9 (STEP UP T2D), 72 weeks[1](https://pepvault.app/guides/glp-1-not-working#source-1) | 7.2 mg | 83.7% | 60.7% | 39.8% |
| Zepbound Study 2 (SURMOUNT-2), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | Placebo | 32.5% | 9.5% | 2.7% |
| Zepbound Study 2 (SURMOUNT-2), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | 10 mg | 79.2% | 60.5% | 39.7% |
| Zepbound Study 2 (SURMOUNT-2), 72 weeks[2](https://pepvault.app/guides/glp-1-not-working#source-2) | 15 mg | 82.8% | 64.8% | 48.0% |

The diabetes labels' own trials, run at diabetes doses, show smaller averages still. In Ozempic's 30-week trial of the drug on its own, people lost 3.8 kg on 0.5 mg and 4.7 kg on 1 mg, against 1.2 kg on placebo[3](https://pepvault.app/guides/glp-1-not-working#source-3). In Mounjaro's 40-week trial against semaglutide 1 mg, the semaglutide group lost 5.7 kg and the tirzepatide groups 7.6, 9.3 and 11.2 kg on 5, 10 and 15 mg[4](https://pepvault.app/guides/glp-1-not-working#source-4). A 2026 meta-analysis of 33 semaglutide trials found that a third of all participants did not reach 5%, and that up to 79.8% of those with type 2 diabetes did not reach 10%[9](https://pepvault.app/guides/glp-1-not-working#source-9).

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Steady state](https://pepvault.app/glossary/steady-state)
- [Titration](https://pepvault.app/glossary/titration)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)

## Do slow starters catch up?

On tirzepatide, most did. A post-hoc analysis (pepvault.app/glossary/post-hoc-analysis), a second look at trial data after the trial ended, sorted 1,545 participants of SURMOUNT-1, the 72-week trial behind Zepbound[6](https://pepvault.app/guides/glp-1-not-working#source-6), who took at least 75% of their doses, by their loss at week 12[7](https://pepvault.app/guides/glp-1-not-working#source-7). 278 of them, 18%, had lost under 5% by then. By week 24, 70% of these late responders had passed 5%; by week 72, 90% had, after about 25 weeks on average.

| SURMOUNT-1, at week 72[7](https://pepvault.app/guides/glp-1-not-working#source-7) | Late responders (under 5% at week 12) | Early responders (5% or more at week 12) |
| --- | --- | --- |
| Average loss, all doses | 11.0% | 22.5% |
| Average loss on 5, 10 and 15 mg | 8.3%, 11.4%, 13.6% | 18.4%, 24.1%, 24.9% |
| Lost 10% or more | 59% | 97% |
| Lost 15% or more | 30% | 84% |

Only 28 people, 1.8% of the whole group, still had under 5% at week 72[7](https://pepvault.app/guides/glp-1-not-working#source-7). Late responders were more often men (45% against 30%) and started heavier (110.2 against 103.6 kg). The authors, most of them Lilly employees, write that this challenges the usual 12-week check for whether a drug works. A 2026 review finds that no single trait at the start reliably predicts response, and that early response on treatment is the most useful sign there is[10](https://pepvault.app/guides/glp-1-not-working#source-10).

## Does a higher dose or a different GLP-1 help?

Wegovy's label allows 7.2 mg 'for patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated'; in STEP UP, 7.2 mg averaged an 18.8% loss at 72 weeks against 15.5% on 2.4 mg, counting everyone[1](https://pepvault.app/guides/glp-1-not-working#source-1). Zepbound's label tells prescribers to 'consider treatment response and tolerability when selecting the maintenance dosage'[2](https://pepvault.app/guides/glp-1-not-working#source-2).

Head to head, tirzepatide led. In SURMOUNT-5, 751 adults without diabetes took the highest dose each could tolerate of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Weight fell 20.2% against 13.7%, and more people on tirzepatide reached every mark from 10% to 25%[8](https://pepvault.app/guides/glp-1-not-working#source-8). The trial was open-label, meaning everyone knew which drug they took, and Lilly paid for it. Whether to raise a dose or switch drugs is the prescriber's decision.

## When is a stall a plateau, and when is it time to ask?

A plateau comes to nearly everyone in the end. In a SURMOUNT-1 analysis of people who stayed on tirzepatide and lost 5% or more, the median time to a plateau was 24 to 36 weeks, depending on starting BMI, and about 88 to 90% had reached one by week 72[13](https://pepvault.app/guides/glp-1-not-working#source-13); the guide Retatrutide not working explains why the body pushes back. British guidance sets a clear test. NICE says to consider stopping semaglutide if less than 5% of the starting weight is lost after 6 months[11](https://pepvault.app/guides/glp-1-not-working#source-11), and, for tirzepatide, to decide whether to continue if less than 5% is lost after 6 months on the highest tolerated dose[12](https://pepvault.app/guides/glp-1-not-working#source-12).

1. Write down the date of every dose step and every missed dose, and count the weeks since you reached your current dose.
2. Weigh yourself at the same time of day, three or more mornings a week, and compare weekly averages, never one day against the next.
3. Compare your week and dose with the tables above, using the diabetes rows if you have type 2 diabetes.
4. At six months, and at six months on your highest tolerated dose, work out your loss as a share: kilograms lost, divided by starting weight, times 100.
5. Take the log to your prescriber, who decides on the dose, a switch or another treatment.

<!--promo-->

PepVault's weight log charts every weigh-in over time, and the doctor's report puts your doses, start weight and weight change on one page for the appointment. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1-not-working-inline&mt=8)

<!--/promo-->

**Commonly reported:** the scale holding still for a week or two after a step-up, then moving again; loss arriving in steps rather than a smooth line; appetite creeping back in the last days before the next shot; and a fast start that slows after a few months. In our reading of public reports, 1 of 77 people on tirzepatide and 1 of 41 on semaglutide described no effect at all (pepvault.app/peptides/tirzepatide/reviews and /peptides/semaglutide/reviews).

**When to get help** Change or skip dose steps only with your prescriber, and contact them the same day if vomiting or diarrhoea stops you keeping fluids down, since the labels warn that the fluid loss can strain the kidneys[1](https://pepvault.app/guides/glp-1-not-working#source-1) [2](https://pepvault.app/guides/glp-1-not-working#source-2).

## Where are the labels and trials on PepVault?

- The drugs: pepvault.app/drugs/ozempic, /drugs/wegovy, /drugs/mounjaro, /drugs/zepbound and /drugs.
- The compounds: pepvault.app/peptides/semaglutide/how-long-to-work and /peptides/tirzepatide/how-long-to-work.
- The trials: pepvault.app/research/semaglutide-step-1-2021, /research/semaglutide-step-2-2021, /research/semaglutide-step-up-2025, /research/tirzepatide-surmount-1-2022, /research/tirzepatide-surmount-2-2023, /research/tirzepatide-surmount-5-2025 and /research/tirzepatide-surmount-1-and-surmount-4-2025.
- The terms: pepvault.app/glossary/titration, /glossary/steady-state, /glossary/placebo and /glossary/post-hoc-analysis.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. WEGOVY (semaglutide) injection and tablets. Prescribing information. Novo Nordisk. DailyMed SPL version 19, published June 30, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
2. ZEPBOUND (tirzepatide) injection. Prescribing information. Eli Lilly and Company. DailyMed SPL version 40, published September 2, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
3. OZEMPIC (semaglutide) injection. Prescribing information. Novo Nordisk. DailyMed SPL version 20, published June 10, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
4. MOUNJARO (tirzepatide) injection. Prescribing information. Eli Lilly and Company. DailyMed SPL version 40, published September 2, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
5. Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. [PubMed 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
6. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. [PubMed 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
7. Ard J et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab. 2025. [PubMed 40677091](https://pubmed.ncbi.nlm.nih.gov/40677091/)
8. Aronne LJ et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. [PubMed 40353578](https://pubmed.ncbi.nlm.nih.gov/40353578/)
9. Ko D et al. Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: a meta-analysis of randomized controlled trials. Cell Rep Med. 2026. [PubMed 41850241](https://pubmed.ncbi.nlm.nih.gov/41850241/)
10. Kuryłowicz A, Czupryniak L. Responders vs. non-responders or how to predict the response to GLP-1 or GLP-1/GIP receptor agonist therapy. Diabetes Obes Metab. 2026. [PubMed 42634284](https://pubmed.ncbi.nlm.nih.gov/42634284/)
11. NICE. Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875, recommendation 1.2. [nice.org.uk](https://www.nice.org.uk/guidance/ta875/chapter/1-Recommendations)
12. NICE. Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026, recommendation 1.2. [nice.org.uk](https://www.nice.org.uk/guidance/ta1026/chapter/1-Recommendations)
13. Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. [PubMed 39800653](https://pubmed.ncbi.nlm.nih.gov/39800653/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)

How much weight and fat intermittent fasting lost in the trials (16:8, 5:2, 4:3, alternate-day), set in one table beside the semaglutide and tirzepatide trials.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)

  What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)

  Retatrutide not working? What the trials show: the climb to the top dose, how many people barely responded, why diabetes slows loss, and what a plateau is.

  Read the guide
- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)

  What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)

  Wegovy and Ozempic dosage side by side: both FDA labels' four-week steps, the maintenance doses and the max, why they differ and what the trials saw per dose.

  Read the guide
- Guide · GLP-1s

  ### [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)

  Tirzepatide doses from 2.5 to 15 mg: the Mounjaro and Zepbound label steps, the 4-week rule, maintenance doses, pens and vials, and SURMOUNT-1 weight by dose.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Steady state](https://pepvault.app/glossary/steady-state)
- [Titration](https://pepvault.app/glossary/titration)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
